Krystal Biotech is strategically positioned in the biotech sector with its unique focus on developing genetic medicines for rare diseases, offering a promising investment opportunity. Krystal ...

Transcription and translation are processes a cell uses to make all proteins the body needs to function from information stored in the sequence of bases in DNA. The four bases (C, A, T/U, and G in the ...

Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...

AMSTERDAM--(BUSINESS WIRE)--Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced that it has entered into a Cooperative ...

The development of mRNA vaccines like Moderna’s for COVID-19 was the result of over 150 years of scientific advancements in genetics, biotechnology and AI. mRNA technology has potential beyond ...

Plant biotechnology has revolutionised our ability to enhance crop performance, conserve endangered species and understand the intricate genetic architectures underlying plant diversity. This field ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global regulations. Considering the advancements, fundamentally solid biotech stocks ...

PLOS Biology, a peer-reviewed open-access journal, recently asked “eight leaders” for their predictions about the next ten years in genetics and genomics. Many responses acknowledge that this task may ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Shares of UniQure, the Netherlands-based gene therapy ...

Most biotechs don't have a diversified business model. They typically develop hardware, diagnostic tests, or drugs, as well as some of the associated platform technologies. But a few competitors, like ...

23andMe is scaling up its pipeline with the help of its collaborators. Fulgent Genetics is rapidly building its oncology testing business. 23andMe's strategy will take longer to pay off, but it could ...